FierceBiotech· @FierceBiotech · X·· 25 天前AI 评分42
AI 导读
在 ESMO 上公布令人鼓舞的卵巢癌数据后,Zentalis 已在为 WEE1 抑制剂 azenosertib 的潜在美国上市做准备。CEO Julie Eastland 向 Fierce 讲述了这家生物技术公司为何看到了商业机会。https://www.fiercebiotech.com/biotech/esmo-zentalis-already-dreaming-launching-wee1-drug-after-great-result #ESMO26
正文
Zentalis is already preparing for a potential U.S. launch of its WEE1 inhibitor azenosertib after encouraging ovarian cancer data at ESMO. CEO Julie Eastland tells Fierce why the biotech sees a commercial opportunity. https://www.fiercebiotech.com/biotech/esmo-zentalis-already-dreaming-launching-wee1-drug-after-great-result #ESMO26
来源:FierceBiotech · x.com